| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
24,140,000 |
| Market
Cap: |
732.89(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$26.52 - $75.32 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Gemeni Therapeutics is a clinical-stage precision medicine company developing therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). Co.'s lead product candidate, GEM103, is a recombinant form of the human complement factor H protein and is designed to address complement hyperactivity and overall dysregulation caused by loss of function mutations thus restoring retinal health in patients with AMD.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
652,175 |
| Total Buy Value |
$0 |
$0 |
$0 |
$15,000,025 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
28,918 |
1,809,345 |
3,899,867 |
3,922,367 |
| Total Sell Value |
$2,009,702 |
$108,295,610 |
$210,114,411 |
$210,161,436 |
| Total People Sold |
2 |
8 |
12 |
13 |
| Total Sell Transactions |
3 |
33 |
52 |
53 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Macdonald Brian Richard |
Chief Innovation Officer |
• – – |
2023-06-28 |
4 |
AS |
$49.24 |
$254,795 |
D/D |
(5,100) |
22,300 |
|
-5% |
|
| Novo A/s |
10% Owner |
– – • |
2023-06-28 |
4 |
S |
$46.10 |
$57,625,000 |
D/D |
(1,250,000) |
1,090,772 |
|
5% |
|
| Orbimed Genesis Gp Llc |
Director |
– • • |
2023-02-15 |
4 |
B |
$23.00 |
$2,500,008 |
I/I |
108,696 |
299,205 |
2.25 |
118% |
|
| Ashiya Mona |
Director |
– • • |
2023-02-15 |
4 |
B |
$23.00 |
$2,500,008 |
I/I |
108,696 |
299,205 |
2.25 |
118% |
|
| Blavatnik Len |
10% Owner |
– – • |
2023-02-15 |
4 |
B |
$23.00 |
$10,000,009 |
D/D |
434,783 |
3,141,759 |
2.45 |
118% |
|
| Bitterman Kevin |
Director |
– • – |
2022-12-29 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
51,000 |
|
- |
|
| Blavatnik Len |
10% Owner |
– – • |
2022-12-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,706,976 |
|
2,399% |
|
| Novo A/s |
10% Owner |
– – • |
2022-12-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,340,772 |
|
2,399% |
|
| Ashiya Mona |
Director |
– • • |
2022-12-29 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,160,941 |
|
2,399% |
|
| Atlas Venture Associates Opportunity Ii, Llc |
10% Owner |
– – • |
2022-12-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
218,326 |
|
2,399% |
|
| Nicholson Donald William |
Director |
– • – |
2022-12-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,332 |
|
2,399% |
|
| Bitterman Kevin |
Director |
– • – |
2022-12-29 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,173,482 |
|
2,399% |
|
| Savage William Jacob |
Chief Medical OfficerOfficer |
• – – |
2022-12-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,325 |
|
2,399% |
|
| Macdonald Brian Richard |
Chief Innovation OfficerOffice |
• – – |
2022-12-29 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,288 |
|
2,399% |
|
| Macdonald Brian Richard |
Chief Innovation OfficerOffice |
• – – |
2022-12-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
27,400 |
|
2,399% |
|
| Bryce Joanne |
Chief Financial OfficerOfficer |
• – – |
2022-12-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,452 |
|
2,399% |
|
| Atlas Venture Associates Opportunity I, Llc |
10% Owner |
– – • |
2022-12-29 |
4 |
A |
$0.00 |
$0 |
I/I |
882,224 |
955,156 |
|
- |
|
| Atlas Venture Associates Opportunity I, Llc |
10% Owner |
– – • |
2022-12-29 |
4 |
A |
$0.00 |
$0 |
D/D |
1,835,799 |
2,237,303 |
|
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • • |
2022-12-29 |
4 |
A |
$0.00 |
$0 |
I/I |
2,160,941 |
1,139,507 |
|
- |
|
| Leonard Braden Michael |
10% Owner |
– – • |
2022-10-26 |
4 |
S |
$2.09 |
$47,025 |
D/D |
(22,500) |
247,500 |
|
-938% |
|
| Piekos Brian |
CFO |
• – – |
2022-05-31 |
4 |
A |
$1.09 |
$10,856 |
D/D |
9,960 |
17,615 |
|
- |
|
| Leonard Braden Michael |
10% Owner |
– – • |
2022-04-13 |
4 |
B |
$1.52 |
$291,604 |
I/I |
191,769 |
5,000,000 |
1.5 |
2% |
|
| Leonard Braden Michael |
10% Owner |
– – • |
2022-04-12 |
4 |
B |
$1.42 |
$290,193 |
I/I |
203,744 |
4,808,231 |
1.5 |
11% |
|
| Leonard Braden Michael |
10% Owner |
– – • |
2022-04-12 |
4 |
B |
$1.37 |
$75,075 |
D/D |
55,000 |
270,000 |
2.45 |
11% |
|
| Leonard Braden Michael |
10% Owner |
– – • |
2022-04-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
270,000 |
|
20% |
|
117 Records found
|
|
Page 4 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.41 (1.33%) 
